Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 10/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL6111434 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| Hexane SCHEMBL9340228 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL21899639 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL8517652 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| Hexane SCHEMBL534288 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL14208157 | 0.97 | LMNA (0.52) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL6354364 | 0.97 | LMNA (0.52) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL2344964 | 0.97 | LMNA (0.52) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL2350132 | 0.95 | LMNA (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL2348904 | 0.95 | LMNA (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115627563-A | Diluent of treating agent for synthetic fiber and method for producing synthetic fiber | 竹本油脂株式会社 | 2023-01-20 | — | — | CN | disclosed |
| EP-3656897-B1 | DILUTED SOLUTION OF SYNTHETIC FIBER TREATMENT AGENT, AND METHOD FOR MANUFACTURING SYNTHETIC FIBERS | TAKEMOTO OIL & FAT CO LTD (JP) | 2023-01-04 | — | — | EP | disclosed |
| CN-111065767-B | Diluent of treating agent for synthetic fiber and method for producing synthetic fiber | 竹本油脂株式会社 | 2022-11-15 | — | — | CN | disclosed |
| EP-3656897-A1 | DILUTED SOLUTION OF SYNTHETIC FIBER TREATMENT AGENT, AND METHOD FOR MANUFACTURING SYNTHETIC FIBERS | Takemoto Yushi Kabushiki Kaisha (JP) | 2020-05-27 | — | — | EP | disclosed |
| CN-103710969-B | Treating agent for synthetic fiber, aqueous solution of treating agent for synthetic fiber, method for treating synthetic fiber, and synthetic fiber | TAKEMOTO OIL & FAT CO LTD | 2015-05-20 | — | — | CN | disclosed |
| US-8907126-B2 | Tyrosine derivative and method for producing tyrosine derivative | NARD INSTITUTE, LTD. (JP) | 2014-12-09 | — | — | US | disclosed |
| US-8834735-B2 | Processing agents for synthetic fibers, aqueous liquids thereof, processing methods for synthetic fibers and synthetic fibers | TAKEMOTO YUSHI KABUSHIKI KAISHA (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2712956-B1 | Processing agents for synthetic fibers, aqueous liquids thereof, processing methods for synthetic fibers and synthetic fibers | TAKEMOTO OIL & FAT CO LTD (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20140187814-A1 | TYROSINE DERIVATIVE AND METHOD FOR PRODUCING TYROSINE DERIVATIVE | NARD INSTITUTE, LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| CN-103710969-A | Treating agent for synthetic fiber, aqueous solution of treating agent for synthetic fiber, method for treating synthetic fiber, and synthetic fiber | TAKEMOTO OIL & FAT CO LTD | 2014-04-09 | — | — | CN | disclosed |
| CN-101992076-B | Chiral binaphthyl chromatographic stationary phase and preparation method and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2012-05-30 | — | — | CN | disclosed |
| US-8129163-B2 | Gene suitable for alcohol dehydrogenase, vector and transformant | KANEKA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8008293-B2 | Bicyclic oxomorpholine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| CN-101992076-A | Chiral binaphthyl chromatogram immobile phase, and preparation method and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2011-03-30 | — | — | CN | disclosed |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100035317-A1 | NOVEL ALCOHOL DEHYDROGENASE, GENE FOR THE ALCOHOL DEHYDROGENASE, VECTOR, TRANSFORMANT, AND METHOD FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOL BY USING THEM | KANEKA CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-2125829-A2 | BICYCLIC OXOMORPHOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2096165-A1 | NOVEL ALCOHOL DEHYDROGENASE, GENE FOR THE ALCOHOL DEHYDROGENASE, VECTOR, TRANSFORMANT, AND METHOD FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOL BY USING THEM | Kaneka Corporation (JP) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008108378-A2 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-12 | — | — | WO | disclosed |
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187814-A1 | TYROSINE DERIVATIVE AND METHOD FOR PRODUCING TYROSINE DERIVATIVE | TH, MTNR1A, MTNR1B | SMN1; SMN2 4448/4885LMNA 3494/4885ALDH1A1 1457/4885 |
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | OPRM1, OPRK1, OPRD1 | SMN1; SMN2 2131/4885LMNA 3886/4885ALDH1A1 2062/4885 |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | OPRM1, OPRK1, OPRD1 | SMN1; SMN2 1555/4885LMNA 3017/4885ALDH1A1 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.